{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-24-000053","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.272533+00:00","generated_at":"2026-05-30T05:15:06.804179+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AnaptysBio Q3 net loss $1.14/shr; cash $458M; Phase 2b data catalysts ahead","bullets":["Net loss $32.9M ($1.14/shr) vs $37.3M ($1.41/shr) year-ago; nine-month loss $4.46/shr.","Collaboration revenue $30M in Q3 vs $3.3M year-ago due to Jemperli milestone and royalties.","Cash and investments $458M; reaffirms cash runway through year-end 2026.","Top-line Phase 2b data for ANB032 in atopic dermatitis expected December 2024.","Top-line Phase 2b data for rosnilimab in RA expected February 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-24-000053","json":"https://secwatch.observer/filing/0001370053-24-000053.json","markdown":"https://secwatch.observer/filing/0001370053-24-000053.md","text":"https://secwatch.observer/filing/0001370053-24-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000053/0001370053-24-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000053/anab-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:15:06.804179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}